416 related articles for article (PubMed ID: 18551610)
1. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
[TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
4. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1354-62. PubMed ID: 18551609
[TBL] [Abstract][Full Text] [Related]
5. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
7. Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells.
Colombatto P; Ciccorossi P; Maina AM; Civitano L; Oliveri F; Coco B; Romagnoli V; Bonino F; Brunetto MR
Clin Pharmacol Ther; 2008 Aug; 84(2):212-5. PubMed ID: 18388885
[TBL] [Abstract][Full Text] [Related]
8. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
11. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C.
Sauleda S; Esteban JI; Altisent C; Puig L; Esteban R; Guardia J
Thromb Haemost; 2000 Jun; 83(6):807-10. PubMed ID: 10896229
[TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
[TBL] [Abstract][Full Text] [Related]
13. Parameters predicting response to alpha-interferon treatment in chronic hepatitis C.
Glück T; Seelig R; Dette S; Bühring HJ; Renz M; Kwon S; Wiedmann KH; Weber P
Hepatogastroenterology; 1997; 44(14):484-91. PubMed ID: 9164523
[TBL] [Abstract][Full Text] [Related]
14. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Chen J; Shi J; Xie WF; Zeng X; Lin Y
Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
[TBL] [Abstract][Full Text] [Related]
18. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
[TBL] [Abstract][Full Text] [Related]
19. Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment.
Sarin SK; Kumar M; Hissar S; Sharma BC
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):374-80. PubMed ID: 16911934
[TBL] [Abstract][Full Text] [Related]
20. Evolution of hepatitis C virus quasispecies during therapy with IL2 combinated to alpha interferon and ribavirin.
Boulestin A; Sandres-Saune K; Alric L; Pipy B; Dubois M; Vinel JP; Izopet J
Antivir Ther; 2005; 10(4):499-504. PubMed ID: 16038475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
